...
首页> 外文期刊>BMC Genomics >A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions
【24h】

A hybrid machine learning-based method for classifying the Cushing's Syndrome with comorbid adrenocortical lesions

机译:基于混合机器学习的库欣综合症合并肾上腺皮质病变分类方法

获取原文
   

获取外文期刊封面封底 >>

       

摘要

BackgroundThe prognosis for many cancers could be improved dramatically if they could be detected while still at the microscopic disease stage. It follows from a comprehensive statistical analysis that a number of antigens such as hTERT, PCNA and Ki-67 can be considered as cancer markers, while another set of antigens such as P27KIP1 and FHIT are possible markers for normal tissue. Because more than one marker must be considered to obtain a classification of cancer or no cancer, and if cancer, to classify it as malignant, borderline, or benign, we must develop an intelligent decision system that can fullfill such an unmet medical need.ResultsWe have developed an intelligent decision system using machine learning techniques and markers to characterize tissue as cancerous, non-cancerous or borderline. The system incorporates learning techniques such as variants of support vector machines, neural networks, decision trees, self-organizing feature maps (SOFM) and recursive maximum contrast trees (RMCT). These variants and algorithms we have developed, tend to detect microscopic pathological changes based on features derived from gene expression levels and metabolic profiles. We have also used immunohistochemistry techniques to measure the gene expression profiles from a number of antigens such as cyclin E, P27KIP1, FHIT, Ki-67, PCNA, Bax, Bcl-2, P53, Fas, FasL and hTERT in several particular types of neuroendocrine tumors such as pheochromocytomas, paragangliomas, and the adrenocortical carcinomas (ACC), adenomas (ACA), and hyperplasia (ACH) involved with Cushing's syndrome. We provided statistical evidence that higher expression levels of hTERT, PCNA and Ki-67 etc. are associated with a higher risk that the tumors are malignant or borderline as opposed to benign. We also investigated whether higher expression levels of P27KIP1 and FHIT, etc., are associated with a decreased risk of adrenomedullary tumors. While no significant difference was found between cell-arrest antigens such as P27KIP1 for malignant, borderline, and benign tumors, there was a significant difference between expression levels of such antigens in normal adrenal medulla samples and in adrenomedullary tumors.ConclusionsOur frame work focused on not only different classification schemes and feature selection algorithms, but also ensemble methods such as boosting and bagging in an effort to improve upon the accuracy of the individual classifiers. It is evident that when all sorts of machine learning and statistically learning techniques are combined appropriately into one integrated intelligent medical decision system, the prediction power can be enhanced significantly. This research has many potential applications; it might provide an alternative diagnostic tool and a better understanding of the mechanisms involved in malignant transformation as well as information that is useful for treatment planning and cancer prevention.
机译:背景技术如果仍处于微观疾病阶段就可以检测出许多癌症的预后,则可以大大改善其预后。从全面的统计分析得出,许多抗原(例如hTERT,PCNA和Ki-67)可以被视为癌症标志物,而另一组抗原(例如P27KIP1和FHIT)则可能是正常组织的标志物。因为必须考虑多个标志才能获得癌症分类或没有癌症分类,并且如果要将癌症分类为恶性,边缘性或良性,我们必须开发一种智能的决策系统来满足这种未满足的医疗需求。已经使用机器学习技术和标记物开发了一种智能决策系统,以将组织表征为癌性,非癌性或边缘性。该系统结合了学习技术,例如支持向量机,神经网络,决策树,自组织特征图(SOFM)和递归最大对比度树(RMCT)的变体。我们开发的这些变体和算法倾向于根据从基因表达水平和代谢谱获得的特征来检测微观病理变化。我们还使用了免疫组织化学技术来测量多种抗原类型中许多抗原(例如细胞周期蛋白E,P27KIP1,FHIT,Ki-67,PCNA,Bax,Bcl-2,P53,Fas,FasL和hTERT)的基因表达谱神经内分泌肿瘤,如嗜铬细胞瘤,神经节旁瘤和与库欣综合征有关的肾上腺癌(ACC),腺瘤(ACA)和增生(ACH)。我们提供的统计证据表明,hTERT,PCNA和Ki-67等的较高表达水平与肿瘤为良性或恶性或交界性的较高风险有关。我们还调查了P27KIP1和FHIT等较高的表达水平是否与肾上腺髓质瘤的风险降低有关。虽然对于恶性,交界性和良性肿瘤,细胞逮捕性抗原(例如P27KIP1)之间没有发现显着差异,但正常肾上腺髓质样本和肾上腺髓质瘤中此类抗原的表达水平之间却存在显着差异。不仅可以使用不同的分类方案和特征选择算法,还可以使用诸如增强和装袋之类的整体方法来努力提高各个分类器的准确性。显然,将各种机器学习和统计学习技术适当地组合到一个集成的智能医疗决策系统中,可以大大提高预测能力。这项研究具有许多潜在的应用。它可能提供替代的诊断工具,并更好地了解恶性转化所涉及的机制以及对治疗计划和癌症预防有用的信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号